Moreover, a GLP-1R/GIPR dual agonist (Tirzepatide) with promising results for the treatment of T2D in clinical trials (18) has recently been reported to show pronounced G protein bias at the GLP-1R, although not at the GIPR (19). Here, GIPR is linked to type 2 diabetes mellitus.